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Background: Various mushrooms have been used in folk medicine for the treatment of lifestyle diseases in eastern
countries, and several compounds that modulate the immune system, lower blood lipid levels, and inhibit tumor
and viral action have been isolated. The fruiting body of Panellus serotinus (Mukitake) is recognized in Japan as one
of the most delicious edible mushrooms, and previous studies have demonstrated that the dietary intake of
powdered whole Mukitake or Mukitake extracts prevents the development of non-alcoholic fatty liver disease
(NAFLD) in leptin-resistant db/db mice. In the present study, we evaluated the effect of the Mukitake diet on the
pathogenesis of metabolic disorders in leptin-deficient ob/ob mice.
Results: After 4 weeks of feeding, hepatomegaly, hepatic lipid accumulation, and elevated hepatic injury markers in
the serum were markedly alleviated in Mukitake-fed ob/ob mice compared with control mice. Moreover, the mild
hyperlipidemia in control ob/ob mice was attenuated and the elevated atherogenic index was reduced in
Mukitake-fed ob/ob mice. These effects were partly attributable to the suppression of hepatic lipogenic enzyme
activity due to the Mukitake diet.
Conclusion: The current results showed that Mukitake supplementation is beneficial for the alleviation of NAFLD
and dyslipidemia in obese, diabetic ob/ob mice.
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Diet contributes to the development and prevention of
lifestyle-related diseases, and various mushrooms have
been used in folk medicine for the treatment of lifestyle-
related diseases in eastern countries [1-3]. Several lines
of evidence support the nutraceutical effect of edible
mushrooms, and many compounds that modulate the
immune system, lower blood lipid levels, and inhibit
tumors and viral action have been isolated from various
mushrooms, such as Shiitake and Hatakeshimeji [1-6].
Panellus serotinus belongs to the same family of mycelia
as Lentinus edodes (Shiitake) and Lyophyllum decastes
(Hatakeshimeji), and its fruiting body (Mukitake) is* Correspondence: yanagitt@nisikyu-u.ac.jp
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reproduction in any medium, provided the orrecognized in Japan as one of the most delicious edible
mushrooms. The technology for the artificial cultivation
of Mukitake in plastic greenhouses has recently been
developed [7] and has enabled the constant provision of
Mukitake mushrooms in the market.
Metabolic syndrome, which comprises a cluster of
metabolic abnormalities, such as hyperlipidemia, dia-
betes mellitus, and hypertension, is a widespread and in-
creasingly prevalent disease in industrialized countries
and contributes to the increase in cardiovascular mor-
bidity and mortality [8,9]. Nonalcoholic fatty liver dis-
ease (NAFLD) is often associated with features of
metabolic syndrome and is emerging as the most com-
mon liver disease worldwide [10-13]. Dyslipidemia is a
lipid abnormality in the blood, and hyperlipidemia is
prevalent due to westernized diets and the disadvantages
of modern lifestyles. Insulin resistance can also lead to
dyslipidemia. Many studies evaluating the effects of
functional food components on the pathogenesis oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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out in genetic leptin-resistant db/db mice and leptin-
deficient ob/ob mice [14,15]. db/db mice have a missense
mutation in the leptin receptor gene [14], and ob/ob
mice have an inherited deficiency of the leptin gene [15],
and they suffer from hyperphagia and develop a syn-
drome with multiple metabolic and hormonal disorders,
including NAFLD and dyslipidemia, which shares many
features with human metabolic syndrome. A recent
study suggested that pathological features of liver lesions
and the response to diets are slightly different between
db/db and ob/ob mice [16].
In previous studies, we demonstrated that the dietary
intake of powdered whole Mukitake or Mukitake
extracts prevented the development of NAFLD, partly
through the suppression of hepatic lipogenesis and nor-
malized adipocytokine profiles, in leptin-resistant db/db
mice [17,18]. In the present study, we evaluated the ef-
fect of the Mukitake diet on the pathogenesis of meta-
bolic disorders in leptin-deficient ob/ob mice.
Materials and methods
Animals and diets
All aspects of the experiment were conducted according
to the guidelines provided by the ethical committee for
experimental animal care at Saga University. Five-week
-old male C57BL/6J mice and ob/ob mice were pur-
chased from Japan SLC (Shizuoka, Japan). The mice
were individually housed in plastic cages in a
temperature-controlled room (24C) under a 12-h light/
dark cycle. The basal semisynthetic diets were prepared
according to recommendations of the AIN-76 [19]
(Table 1). Mukitake mushrooms were provided by the
Forestry Research Institute of the Saga Prefecture, and
general components of the samples were routinely deter-
mined according to official AOAC methods. The ob/ob




Corn starch 15.0 8.9
Cellulose 5.0 3.1
Mineral mixture (AIN 76) 3.5 3.5
Vitamin mixture (AIN 76) 1.0 1.0
DL-Methionine 0.3 0.3
Choline bitartrate 0.2 0.2
Corn oil 5.0 5.0
Mukitake powder * 0.0 10.0
Sucrose 50.0 49.2
* Carbohydrate: 62.5%, Fiber: 19.2%, Protein: 12.5%, Ash: 3.8%, Fat: 1.9%.were fed one of two diets (Table 1): a semisynthetic
AIN-76 diet (Control group) or a semisynthetic AIN-76
diet supplemented with 10% air-dried Mukitake powder
instead of casein, corn starch, and cellulose (Mukitake
group). C57BL/6J mice (n = 6), the progenitors of the
ob/ob mice, were fed the same diet as the ob/ob mice in
the Control group (Normal group). The mice received
the diets ad libitum using Rodent CAFE (KBT Oriental
Co. Ltd., Saga, Japan) for 4 weeks. At the end of the
feeding period, the mice were sacrificed by exsanguin-
ation from the heart under pentobarbital sodium salt
anesthesia after a 9-h starvation period. Abdominal
white adipose tissue and livers were excised immediately,
and the serum was separated from the blood.Measurement of serum parameters
Serum lipoproteins were analyzed using an on-line dual
enzymatic method for the simultaneous quantification of
triglyceride and cholesterol using high-performance li-
quid chromatography at Skylight Biotech Inc. (Akita
Japan), as described elsewhere [20]. The activities of as-
partate aminotransferase (AST) and alanine aminotrans-
ferase (ALT) in the serum were measured using
commercial enzyme assay kits (Wako Pure Chemicals,
Tokyo, Japan). Serum adiponectin and insulin levels
were measured using commercial mouse ELISA kits
(Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan; Shibayagi
Co. Ltd., Gunma, Japan, respectively).Measurement of triglyceride and cholesterol levels in the
liver
Liver lipids were extracted, and the concentrations of tri-
glyceride and cholesterol were measured as described
previously [21,22].Assays of hepatic enzyme activity
The preparation of hepatic subcellular fractions was
described previously [23]. The enzyme activities of fatty
acid synthase (FAS), glucose 6-phosphate dehydrogenase
(G6PDH), and malic enzyme in the cytosomal fraction,
carnitine palmitoyltransferase (CPT) in the mitochon-
drial fraction, and phosphatidate phosphohydrolase
(PAP) in the microsomal fraction were determined as
described elsewhere [24].Statistical analysis
All values are expressed as the means ± standard error.
The data were analyzed using a one-way ANOVA, and
all differences were analyzed using the Tukey-Kramer
post-hoc test (KaleidaGraph; Synergy Software, Reading,
PA, USA). Differences were considered to be significant

























Figure 2 Hepatic injury marker activities in C57BL/6J and ob/ob
mice. Mice were fed the control diet or Mukitake diet for 4 weeks.
Values are expressed as the mean ± standard error for six mice. See
Table 1 for the composition of diets. abc Different superscripted
letters indicate a significant difference at P < 0.05.
Table 2 Effect of Mukitake diet on growth parameters in




Total 23.7 ± 2.5 a 54.4 ± 6.2 b 33.2 ± 1.6 a
CM 0.0283 ±0.0170 0.432 ± 0.227 0.205 ± 0.067
VLDL 13.2 ± 2.1 16.8 ± 3.7 11.3 ± 1.4
LDL 8.53 ± 0.45 a 27.0 ± 1.7 b 14.9 ± 0.7 c
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Effect of dietary Mukitake on the pathogenesis of NAFLD
in ob/ob mice
The food intake (Normal, 76.8 ± 2.8; Control, 129 ± 5 g,
p < 0.05) and final body weight (Normal, 24.6 ± 0.5; Con-
trol, 41.2 ± 0.7 g, p < 0.05) were significantly higher in
the control diet-fed ob/ob mice than the C57BL/6J mice
after the 4-week feeding period. After being fed the con-
trol diets for 4 weeks, the ob/ob mice developed marked
abdominal obesity (Normal, 5.97 ± 0.22; Control, 22.3 ±
0.5 g/100 g bw, p < 0.05) and hepatomegaly (Normal,
3.78 ± 0.09; Control, 10.7 ± 0.3 g/100 g bw, p < 0.05). Al-
though the two groups of ob/ob mice did not differ in
initial body weight (Control, 35.4 ± 1.1; Mukitake, 35.5 ±
0.8 g) or food intake (Control, 129 ± 5; Mukitake, 129 ±
3 g), the liver weight was 21% lower in Mukitake-fed ob/
ob mice (Control, 10.7 ± 0.3; Mukitake, 8.42 ± 0.18 g/100 g
bw, p < 0.05). The reduction was associated with decreased
triglyceride (32%) and cholesterol (31%) accumulation in
the liver (Figure 1). The effects of dietary Mukitake on
hepatic injury marker levels were also evaluated, and the
activity of ALT tended to decrease (by 26%) and AST ac-
tivity was markedly decreased (by 32%, p < 0.05) in the
serum of Mukitake-fed ob/ob mice compared to control-
fed ob/ob mice (Figure 2). Consistent with previous
reports that indicated the alleviation of hepatomegaly and
hepatic steatosis in Mukitake-fed db/db mice [17,18], diet-
ary Mukitake also protected ob/ob mice from the develop-
ment of NAFLD.
Effect of dietary Mukitake on the pathogenesis of
dyslipidemia in ob/ob mice
After the 4-week feeding period, ob/ob mice fed the con-
trol diet had mild hyperlipidemia (Table 2). The serum
triglyceride level was 1.3-fold higher and the serum chol-
esterol level was 2.7-fold higher in control-fed ob/ob
mice than C57BL/6J mice. The Mukitake diet markedly
























Figure 1 Hepatic lipid levels in C57BL/6J and ob/ob mice. Mice
were fed the control diet or Mukitake diet for 4 weeks. Values are
expressed as the mean ± standard error for six mice. See Table 1 for
the composition of diets. abc Different superscripted letters indicate a
significant difference at P < 0.05.in the serum of ob/ob mice (Table 2). Additionally,
Table 2 shows the serum lipoprotein profiles in C57BL/
6J mice and ob/ob mice. Triglyceride levels in the chylo-
micron (CM) and very-low-density lipoprotein (VLDL)
fractions tended to decrease (by 53% and 33%, respect-
ively) and levels in the low-density lipoprotein (LDL)
and high-density lipoprotein (HDL) fractions were de-
creased (by 45% and 34%, respectively) in the Mukitake
group compared with the Control group in ob/ob mice.
The cholesterol levels in all fractions were decreased
in Mukitake-fed ob/ob mice. Moreover, the calculatedHDL 1.89 ± 0.06 a 10.2 ± 1.3 b 6.73 ± 0.46 c
Cholesterol (mg/dl)
Total 100 ± 5 a 273 ± 6 b 206 ± 7 c
CM 0.0283 ± 0.0048 a 0.252 ± 0.028 b 0.157 ± 0.008 c
VLDL 2.69 ± 0.34 a 12.1 ± 1.5 b 5.74 ± 0.35 c
LDL 10.0 ± 1.0 a 71.1 ± 2.7 b 36.8 ± 1.9 c
HDL 87.2 ± 4.2 a 190 ± 4 b 164 ± 5 c
Atherogenic index
(VLDL + LDL)/HDL 0.145 ± 0.010 a 0.438 ±0.015 b 0.259 ± 0.005 c
Insulin (ng/ml) 0.886 ± 0.248 a 52.1 ± 13.1 b 56.3 ± 9.8 b
Adiponectin (μg/ml) 29.6 ± 0.6 a 11.6 ± 0.5 b 12.3 ± 0.3 b
Values are expressed as the mean ± standard error for six mice.
abc Different superscripted letters indicate a significant difference at P < 0.05.
CM; chylomicron, VLDL; very-low-density lipoprotein, LDL; low-density
lipoprotein, HDL; high-density lipoprotein.
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HDL) was significantly lower (by 41%) in Mukitake-fed
ob/ob mice compared with control-fed ob/ob mice. These
results suggest that dietary Mukitake can alleviate dysli-
pidemia in obese, diabetic ob/ob mice and has an anti-
atherogenic property.
Effect of dietary Mukitake on hyperinsulinemia and serum
adiponectin levels in ob/ob mice
Insulin resistance, as well as compensatory hyperinsuli-
nemia, are the essential first pathologic step in the devel-
opment of NAFLD and dyslipidemia [25-27]. In fact,
hepatic steatosis and hyperlipidemia have been proposed
to be a feature of insulin resistance syndrome along with
type 2 diabetes and visceral obesity [25-27]. Adiponectin
is one of the most abundant secretory proteins produced
by adipose tissue in rodents and humans and is sug-
gested to play a protective role in insulin resistance [28].
In obese, diabetic ob/ob mice (Control group), serum in-
sulin levels were markedly increased and serum adipo-
nectin levels were significantly decreased compared with
the C57BL/6J mice (Normal group) (Table 2). Our previ-
ous study indicated that powdered whole Mukitake and
Mukitake extracts tended to alleviate hyperinsulinemia
through increasing serum adiponectin levels in db/db
mice [17,18]. In the present study, however, the Mukitake
diet did not affect serum adiponectin levels or improve
hyperinsulinemia in ob/ob mice. The results suggest that
the alleviating effect of the Mukitake diet on the patho-
genesis of NAFLD and dyslipidemia appears to be inde-



























Figure 3 Activities of hepatic enzymes related to triglyceride metabo
Mukitake diet for 4 weeks. Values are expressed as the mean ± standard err
superscripted letters indicate a significant difference at P < 0.05.Effect of dietary Mukitake on hepatic lipid metabolism in
ob/ob mice
The liver is the pivotal organ with regard to lipid metab-
olism; thus, its metabolic disruption induces lipid abnor-
mality in the entire body. To further examine the effect
of the Mukitake diet on the liver, the activities of hepatic
enzymes related to triglyceride metabolism were ana-
lyzed (Figure 3). The activities of malic enzyme and
G6PDH, enzymes related to lipogenesis, the activity of
PAP, a key enzyme in triglyceride synthesis, and the ac-
tivity of CPT, a key enzyme in fatty acid β-oxidation,
were not altered by the Mukitake diet in ob/ob mice. On
the other hand, the activity of FAS, a key enzyme in de
novo fatty acid synthesis, was significantly elevated (by
50%) in control diet-fed ob/ob mice compared with the
C57BL/6J mice and reduced (by 18%) in Mukitake-fed
ob/ob mice compared with control diet-fed ob/ob mice.
In agreement with the present results, previous reports
showed that dietary intake of powdered whole Mukitake
or both water extracts and ethanol-extracts from
Mukitake prevented the development of NAFLD with
the suppression of hepatic FAS activities in db/db mice
[17,18]. Because differential analysis between Mukitake
and Shiitake, mycelia from the same family, using liquid
chromatography time-of –flight MS technology revealed
that there are several compounds only exist in Mukitke
extracts [18], further structural identification and evalu-
ation of physiological properties (especially, suppressive
effects on FAS activity) of the compounds would be ne-
cessary in future study. Additionally, given the fact that
hepatic lipid abnormalities initiate a progression of liver






















lism in C57BL/6J and ob/ob mice. Mice were fed the control diet or
or for six mice. See Table 1 for the composition of diets. abc Different
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mia by the Mukitake diet was partially attributable to
the suppression of de nove fatty acid synthesis in the
liver.
Conclusion
In conclusion, our present study showed that Mukitake
supplementaion is beneficial for the inhibition of
NAFLD development in leptin-deficient ob/ob mice be-
sides in leptin-resistant db/db mice. Moreover, this is the
first study showing that Mukitake has beneficial effects
in attenuating possible atherosclerotic processes by re-
ducing the atherogenic index in the serum.
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